The mother of a boy who developed gynecomastia, or male breast growth, after using Risperdal has opened up about the legal proceedings. Benita Pledger and her husband have filed a Risperdal lawsuit against drug manufacturers Janssen Pharmaceuticals alleging that the company manipulated data and hid evidence that the drug caused breast growth in boys.
Pledger told Philly.com she exited the court room because she “had a hard time hearing what the pharmaceutical company was doing” to conceal information about Risperdal gynecomastia. Meanwhile, lawyers and former U.S. Food and Drug Administration commissioner Dr. David Kessler discussed Janssen Pharmaceuticals alleged attempts to withhold or misrepresent safety information concerning Risperdal.
A 2001 Risperdal study found that boys and male adolescents who were being given Risperdal had a higher likelihood of developing gynecomastia, but emails between Janssen employees revealed attempts to re-analyze data to downplay those risks. In December 2013 Janssen and parent company Johnson & Johnson agreed to pay $2.2 billion to settle a Risperdal lawsuits alleging that the company illegally promoted the drug for unapproved uses.